Akebia Therapeutics, Inc. (AKBA) is a Healthcare stock trading at $0.91 (as of 2026-08-21), with a market capitalization of $243.63M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Akebia Therapeutics develops and commercializes kidney disease treatments, including oral investigational vadadustat in Phase III, and marketed products such as Auryxia (ferric citrate) for controlling serum phosphorus in adults with DD-CKD on dialysis.
Near-term profitability depends on scaling net product revenue from marketed therapies, plus any collaboration revenue, while the biggest strategic swing factor is vadadustat progressing through Phase III development.
| Net Product | $0.1B |
| Collaboration | $0.0B |
| Vafsio | $0.0B |
| Vapseo | $0.0B |
| Other | $0.0B |
Business quality (Weak): Good clarity on the company business model and the key commercial KPI (Vafsio patients), but the provided revenue breakdown appears incomplete or overlapping across product lines, so segment interpretation should be handled cautiously.
| Price | $0.91 |
| Market Cap | $243.63M |
| Price / Book | 9.74 |
| Price / Sales | 1.13 |
| FCF Yield | -10.1% |
| DCF Value (model) | $0.06 |
| DCF Upside vs Price | -93.4% |
| Revenue (TTM) | $236.20M |
| Net Margin | -2.3% |
| Revenue Growth (YoY) | 47.5% |
| EPS Growth (YoY) | -93.9% |
| FCF Growth (YoY) | -266.4% |
| Altman Z-Score | -4.72 (distress) |
| Piotroski F-Score | 6/9 (moderate) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | BlackRock, Inc. ($25.98M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | John Butler |
| Employees | 181 |
| Country | US |
| IPO Date | 2014-03-20 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.